ASB2 and acute myeloid leukemia: FTO enhances leukemogenesis and leukemia oncogene-mediated cell transformation by reducing m6A levels on mRNA transcripts of targets such as ASB2 and RARA, thereby regulating their expression and inhibiting all-trans retinoic acid (ATRA)-induced differentiation of AML cells.